Across TCGA pan-cancer cohorts, CHM mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CHM data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CHM mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CHM expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, PDAC, and COAD are the cancer types where CHM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.861	0.131	.001	21	view →
PDAC	DFS	Quartile	All	0.673	0.862	.004	12	view →
COAD	DFS	Median	All	0.876	1.000	.039	6	view →
LSCC	OS	Median	II,III,IV	1.000	0.904	.019	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CHM tumor-vs-normal RNA expression · all CHM data types